Compare BEAM & FIZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BEAM | FIZZ |
|---|---|---|
| Founded | 2017 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Beverages (Production/Distribution) |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 3.3B |
| IPO Year | 2019 | 1994 |
| Metric | BEAM | FIZZ |
|---|---|---|
| Price | $23.08 | $37.30 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 15 | 0 |
| Target Price | ★ $49.85 | N/A |
| AVG Volume (30 Days) | ★ 1.8M | 276.2K |
| Earning Date | 11-03-2026 | 12-10-2026 |
| Dividend Yield | N/A | ★ 8.96% |
| EPS Growth | ★ 82.31 | N/A |
| EPS | N/A | ★ 0.50 |
| Revenue | $24,000.00 | ★ $1,180,552,000.00 |
| Revenue This Year | N/A | $4.20 |
| Revenue Next Year | N/A | $1.42 |
| P/E Ratio | ★ N/A | $72.78 |
| Revenue Growth | ★ 33.33 | N/A |
| 52 Week Low | $20.23 | $28.97 |
| 52 Week High | $38.26 | $38.45 |
| Indicator | BEAM | FIZZ |
|---|---|---|
| Relative Strength Index (RSI) | 40.33 | 61.89 |
| Support Level | $22.65 | $33.63 |
| Resistance Level | $28.19 | $37.90 |
| Average True Range (ATR) | 1.92 | 1.02 |
| MACD | -0.33 | -0.07 |
| Stochastic Oscillator | 0.07 | 74.34 |
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
National Beverage Corp is refreshes America with a distinctive portfolio of sparkling waters, juices, energy drinks and, to a lesser extent, carbonated soft drinks. It focus on developing and delighting consumers with healthier beverages in response to the world-wide shift in consumer buying habits and lifestyles. The company has one reportable segment. It primary market focus is the United States. Its brands are LaCroix, Clear fruit, RIP IT, Everfresh, Shasta, Faygo, OHANA, Ritz, Crystal Bay.